Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. announced that its management will participate in the Van Lanschot Kempen Life Sciences Conference on April 16, 2026, in Amsterdam, The Netherlands. The company, which is developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, will have its COO, Julia Neugebauer, PhD, in attendance. This participation offers an opportunity for investors to engage with the company regarding its clinical-stage programs, including varoglutamstat, a QPCT/L inhibitor being evaluated for diabetic kidney disease.

Disclaimer*

UK 100

Latest directors dealings